---
document_datetime: 2023-09-21 19:59:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-astrazeneca-epar-all-authorised-presentations_en.pdf
document_name: pandemic-influenza-vaccine-h5n1-astrazeneca-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7367047
conversion_datetime: 2025-12-30 01:18:11.436156
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name                             | Strength   | Pharmaceutical Form     | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|---------------------------------------------|------------|-------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/16/1089/001 | Pandemic influenza vaccine H5N1 AstraZeneca | -- 1       | Nasal spray, suspension | Nasal use                 | sprayer (glass)       | 0.2 ml                    | 10 sprayers |

- --1 1 dose (0.2 ml) contains:

Reassortant influenza virus* (live attenuated) of the following strain**:

A/Vietnam/1203/2004 (H5N1) strain (A/Vietnam/1203/2004, MEDI 0141000136) 10 7.0Â±0.5 FFU***

*

propagated in fertilised hens' eggs from healthy chicken flocks.

**

produced in VERO cells by reverse genetic technology. This product contains a genetically modified organism (GMO).

***

fluorescent focus units